EGFR and non-small cell lung carcinoma: Front-line therapy with osimertinib is current standard of care for patients with stage IV NSCLC with EGFR ex19del or L858R mutation and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2 based on the FLAURA trial results demonstrating improved outcomes over first-generation agents (9).